Success Metrics

Clinical Success Rate
100.0%

Based on 1 completed trials

Completion Rate
100%(1/1)
Active Trials
2(67%)
Results Posted
0%(0 trials)

Phase Distribution

Ph phase_2
3
100%

Phase Distribution

0

Early Stage

3

Mid Stage

0

Late Stage

Phase Distribution3 total trials
Phase 2Efficacy & side effects
3(100.0%)

Highest Phase Reached

Phase 2

Trial Status & Enrollment

Completion Rate

100.0%

1 of 1 finished

Non-Completion Rate

0.0%

0 ended early

Currently Active

2

trials recruiting

Total Trials

3

all time

Status Distribution
Active(2)
Completed(1)

Detailed Status

Active, not recruiting1
Recruiting1
Completed1

Development Timeline

Analytics

Development Status

Total Trials
3
Active
2
Success Rate
100.0%
Most Advanced
Phase 2

Trials by Phase

Phase 23 (100.0%)

Trials by Status

active_not_recruiting133%
recruiting133%
completed133%

Recent Activity

2 active trials
Showing 3 of 3
recruitingphase_2

A Study of Avutometinib (VS-6766) and Defactinib in People With Mesonephric Gynecologic Cancer

NCT05787561
active_not_recruitingphase_2

A Study of Avutometinib (VS-6766) v. Avutometinib (VS-6766) + Defactinib in Recurrent Low-Grade Serous Ovarian Cancer With and Without a KRAS Mutation

NCT04625270
completedphase_2

A Study of Avutometinib (VS-6766) + Defactinib in Recurrent KRAS G12V, Other KRAS and BRAF Non-Small Cell Lung Cancer

NCT04620330

Clinical Trials (3)

Showing 3 of 3 trials
NCT05787561Phase 2

A Study of Avutometinib (VS-6766) and Defactinib in People With Mesonephric Gynecologic Cancer

Recruiting
NCT04625270Phase 2

A Study of Avutometinib (VS-6766) v. Avutometinib (VS-6766) + Defactinib in Recurrent Low-Grade Serous Ovarian Cancer With and Without a KRAS Mutation

Active Not Recruiting
NCT04620330Phase 2

A Study of Avutometinib (VS-6766) + Defactinib in Recurrent KRAS G12V, Other KRAS and BRAF Non-Small Cell Lung Cancer

Completed

All 3 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
3